Pathos AI is a Chicago-based clinical-stage biotechnology company using artificial intelligence to re-engineer drug development and advance precision oncology therapeutics. The company applies a causal AI framework that analyzes changes in gene expression associated with overall survival and regulated by a drug's mechanism. Its AI models are fueled by one of the largest multimodal real-world datasets, including patient outcomes, DNA sequencing and RNA sequencing data. Led by CEO Ryan Fukushima, Pathos is using its platform to acquire additional clinical-stage opportunities with phase I results showing a safe and tolerable profile. The company intends to use the latest funds to expand its team of scientists and engineers, accelerate development of its AI-powered drug development platform, and advance its clinical-stage pipeline. This financing and valuation update reflects the company's capital position, bringing total funding to $102M after the Series C.

Total raised

$62M

Funding rounds

1

Latest round

Series C

Latest activity

Oct 2024